Antiparkinsonian and other motor effects of flupirtine alone and in combination with dopaminergic drugs

European Journal of Pharmacology

Volumn 327, Issue 1, 1997, Pages 1-9

  Schmidt, Werner J ^a   Schuster, Gertrud ^a   Wacker, Eva ^a   Pergande, Gabriela ^b  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b ASTA MEDICA AG   (Germany)

Author keywords

Catalepsy; Flupirtine; L DOPA (L dihydroxyphenylalanine); Locomotion; NMDA receptor, antagonistic; Parkinson's disease

Indexed keywords

BENSERAZIDE; FLUPIRTINE; HALOPERIDOL; LEVODOPA; NEUROLEPTIC AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BEHAVIOR; CATALEPSY; CONTROLLED STUDY; DOSE RESPONSE; EXPLORATORY BEHAVIOR; GROOMING; INTRAPERITONEAL DRUG ADMINISTRATION; LOCOMOTION; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PSYCHOMOTOR ACTIVITY; RAT; REARING; SNIFFING;

EID: 0030965170     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(97)89671-9     Document Type: Article

References (48)

1. Bischoff C., Tiedtke P.I. Competitive and non-competitive NMDA-receptor antagonists in spatial learning tasks. Eur. J. Pharmacol. 213:1992;269.
2. Block F., Pergande G., Schwarz M. Flupirtine protects against ischaemic retinal dysfunction in rats. NeuroReport. 5:1994;2630.
3. Block F., Pergande G., Schwarz M. Flupirtine reduces functional and morphological consequences induced by global ischemia in rats. Brain Res. 754:1997;279.
4. Bristow L.J., Thorn L., Tricklebank M.D., Hutson P.H. Competitive NMDA receptor antagonists attenuate the behavioural and neurochemical effects of amphetamine in mice. Eur. J. Pharmacol. 264:1994;353.
5. Bubser M., Keseberg U., Notz P.K., Schmidt W.J. Differential behavioural effects of competitive and non-competitive NMDA receptor antagonists in rats. Eur. J. Pharmacol. 229:1992;75.
6. Carlsson M., Carlsson A. Dramatic synergism between MK-801 and clonidine with respect to locomotor stimulatory effect in monoamine-depleted mice. J. Neural Transm. 77:1989;65.
7. Carlsson M., Carlsson A. Interactions between glutamatergic and monoaminergic systems within the basal ganglia - implications for schizophrenia and Parkinson's disease. Trends Neurosci. 13:1990;272.
8. Chase T.M., Papa S.M., Verhagen Metman L., Mourdian M.M. Striatal glutamatergic dysfunction and extrapyramidal motor behaviour. Behav. Pharmacol. 7(Suppl. 1):1996;14.
9. Friedel H.A., Fitton A. Flupirtine: a review of its pharmacological properties and therapeutic efficacy in pain states. Drugs. 45:1993;548.
10. Greenamyre J.T., O'Brien C.F. N-Methyl-D-aspartate antagonists in the treatment of Parkinson's disease. Arch. Neurol. 48:1991;977.
11. Hauber W., Andersen R. The non-NMDA glutamate receptor antagonist GYKI 52466 counteracts locomotor stimulation and anticataleptic activity induced by the NMDA antagonist dizocilpine. Naunyn-Schmiedeberg's Arch. Pharmacol. 348:1993;486.
12. Herrmann W.M., Hiersemenzl R., Aigner M., Lobisch M., Riethmüller-Winzen H., Michel I. Die Langzeitverträglichkeit von Flupirtin. Offene multizentrische Studie über ein Jahr. Fortschr. Med. 111:1993;266.
13. Hornykiewicz, O., 1979. Brain dopamine in Parkinson's disease and other neurological disturbances. In: Horn, A.S., Korf, J., Westerink, B.M.C. (Eds.), The Neurobiology of Dopamine. Academic Press, London, p. 633.
14. Klockgether T., Turski L. NMDA antagonists potentiate antiparkinsonian actions of L-DOPA in monoamine-depleted rats. Ann. Neurol. 28:1990;539.
15. Kretschmer B.D., Zadow B., Volz T.L., Volz L., Schmidt W.J. The contribution of the different binding sites of the N-methyl-D-aspartate (NMDA) receptor to the expression of behavior. J. Neural Transm. [GenSect.]. 87:1992;23.
16. Kretschmer B.D., Winterscheid B., Danysz W., Schmidt W.J. Glycine site antagonists abolish dopamine D2 but not D1 receptor mediated catalepsy in rats. J. Neural Transm. [GenSect.]. 95:1994;123.
17. Kretschmer B.D., Bubser M., Schmidt W.J. Behavioral and neurochemical actions of the strychnine-insensitive glycine receptor antagonist, 7-chlorokynurenate, in rats. Eur. J. Pharmacol. 280:1995;37.
18. Mehta A.K., Ticku M.K. Role of N-methyl-D-aspartate (NMDA) receptors in experimental catalepsy in rats. Life Sci. 46:1990;37.
19. Million R., Finlay B.R., Whittington J.R. Clinical trial of flupirtine maleate in patients with migraine. Curr. Med. Res. Opin. 9:1984;204.
20. Moroe R., Bullingham R.E.S., Simpson S., O'Sullivan G., Evans P.J.D., McQuay J. Comparison of flupirtine maleate and dihydrocodeine in patients following surgery. Br. J. Anaesth. 55:1983;429.
21. Müller W.E.G., Romero F.J., Perovic S., Pialoglou P., Pergande G. Flupirtine: a neuroprotective agent against β-amyloid-induced apoptosis in vitro. J. Brain Res. 37:1996;575.
22. Müller, W.E.G., Pergande, G., Schleger, C., Ushijima, H., Perovic, S., 1996b. Neurotoxicity in rat cortical cells caused by N-methyl-D-aspartate (NMDA) and gp120 of HIV-1: induction and pharmacological intervention. in: Kuchine, Y., Müller, W.E.G. (Eds.), Apoptosis. Springer-Verlag, Berlin, p. 44.
23. Müller W.E.G., Dobmeyer J.M., Dobmeyer T.S., Pergande G., Perovic S., Leuck J., Rossol R. Flupirtine protects both neuronal cells and lymphocytes against induced apoptosis in vitro: implications for treatment of AIDS patients. Cell Death Diff. 4:1997;51.
24. Müller-Limmroth W. Einfluß des neuen Analgetikums Flupirtin auf die psychomotorische Leistungsfähigkeit des Menschen. Arzneim.-Forsch./Drug Res. 35:1985;1089.
25. Olney J.W., Labruyere J., Price M.T. Pathological changes induced in cerebrocortical neurons by phencyclidine and related drugs. Science. 244:1989;1360.
26. Osborne N.N., Pergande G., Block F., Schwarz M. Immuno-histochemical evidence for flupirtine acting as an antagonist on the N-methyl-D-aspartate and homocysteic acid-induced release of GABA in the rabbit retina. Brain Res. 667:1994;291.
27. Osborne N.N., Schwarz M., Pergande G. Protection of rabbit retina from ischemic injury by flupirtine. Invest. Ophthalmol. Vis. Sci. 37:1996;274.
28. Perovic S., Schleger C., Pergande G., Iskric S., Ushijima H., Rytik P., Müller W.E.G. The triaminopyridine flupirtine prevents cell death in rat cortical cells induced by N-methyl-D-aspartate and gp120 of HIV-1. Eur. J. Pharmacol. 288:1994;27.
29. Perovic S., Pergande G., Ushijima H., Kelve M., Forrest J., Müller W.E.G. Flupirtine partially prevents neuronal injury induced by prion protein fragment and lead acetate. Neurodegeneration. 4:1995;369.
30. Robinson T.E., Becker J.B. Enduring changes in brain and behavior produced by chronic amphetamine administration: a review and evaluation of animal models of amphetamine psychosis. Brain Res. Rev. 11:1986;157.
31. Rückert N.G.H., Schmidt W.J. The sigma receptor ligand 1,3-di-(2-tolyl)guanidine in animal models of schizophrenia. Eur. J. Pharmacol. 233:1993;261.
32. 2+ concentration. Eur. J. Pharmacol. 294:1995;469.
33. Schmidt W.J. Intrastriatal injection of DL-2-amino-5-phosphonovaleric acid (AP-5) induces sniffing stereotypy that is antagonized by haloperidol and clozapine. Psychopharmacology. 90:1986;123.
34. Schmidt W.J. Balance of transmitter activities in the basal ganglia loops. J. Neural Transm. 46(Suppl.):1995;67.
35. Schmidt W.J., Bubser M. Anticataleptic effects of the N-methyl-D-aspartate antagonist MK-801 in rats. Pharmacol. Biochem. Behav. 32:1989;621.
36. Schmidt W.J., Bury D. Behavioural effects of N-methyl-D-aspartate in the anterodorsal striatum of the rat. Life Sci. 43:1988;545.
37. Schmidt W.J., Zadow B., Kretschmer B.D., Hauber W. Anticataleptic potencies of glutamate-antagonists. Amino Acids. 1:1991;225.
38. Schwarz M., Block F., Pergande G. N-Methyl-D-aspartate (NMDA)-mediated muscle relaxant action of flupirtine in rats. NeuroReport. 5:1994;1981.
39. 2-adrenergic mechanisms are involved in the depressant action of flupirtine on spinal reflexes in rats. Eur. J. Pharmacol. 276:1995;247.
40. Schwarz M., Nolden-Koch M., Purr J., Pergande G., Block F. Antiparkinsonian effect of flupirtine in monoamine-depleted rats. J. Neural Transm. 103:1996;581.
41. Seaman, C.A., Sheridan, P.H., Engel, J., Molliere, M., Narang, P.K., Nice, F.J., 1986. Flupirtine. In: Meldrum, B.S., Porter, R.J. (Eds.), New Anticonvulsant Drugs. Libbey, London, p. 135.
42. Szelenyi I., Nickel B. Pharmacological profile of flupirtine, a novel centrally acting, non-opioid analgesic drug. Agents Actions. 32(Suppl.):1991;119.
43. Tiedtke P.I., Bischoff C., Schmidt W.J. MK-801-induced stereotypy and its antagonism by neuroleptic drugs. J. Neural Transm. [GenSect.]. 81:1990;173.
44. Timmann D., Plummer C., Schwarz M., Diener H.C. Influence of flupirtine on human lower limb reflexes. Electroencephalogr. Clin. Neurophysiol. 97:1995;184.
45. Tzschentke T.M., Schmidt W.J. Procedural examination of behavioural sensitisation to morphine: lack of blockade by MK-801, occurrence of sensitised sniffing, and evidence for cross-sensitisation between morphine and MK-801. Behav. Pharmacol. 7:1996;169.
46. Wozniak D.F., Brosnan-Watters G., Nardi A., McEwen M., Corso T.D., Olney J.W., Fix A.S. MK-801 neurotoxicity in male mice: histologic effects and chronic impairment in spatial learning. Brain Res. 707:1996;165.
47. Yoshida Y., Ono T., Kizu A., Fukushima R., Miyagishi T. Striatal N-methyl-D-aspartate receptors in haloperidol-induced catalepsy. Eur. J. Pharmacol. 203:1991;173.
48. Zadow B., Schmidt W.J. The AMPA antagonists NBQX and GYKI 52466 do not counteract neuroleptic-induced catalepsy. Naunyn-Schmiedeberg's Arch. Pharmacol. 349:1994;61.